Key insights
- Medtronic's stock surged on strong Q4 FY2026 results, exceeding revenue and EPS expectations with its best annual top-line growth in a decade. Significant growth in Cardiac Ablation Solutions, particularly in the US, and a dividend increase further boosted investor confidence. The company's FY2027 guidance and strategic investments, including an acquisition, signal continued growth, contributing positively to the healthcare sector and potentially influencing sentiment for similar companies.
Investing.com -- Medtronic stock surged +5.3% in morning trading today, reaching $82.05, after the medical device giant on Wednesday reported fiscal fourth-quarter FY2026 results that topped Wall Street expectations on both revenue and earnings, marking the company’s best annual top-line performance in ten years. Q4 revenue came in at $9.8 billion, rising 9.9% year-over-year and 6.6% on an organic basis, while non-GAAP diluted EPS of $1.55 edged past the analyst consensus of $1.54. For the full fiscal year, revenue reached $36.4 billion, up 8.4% as reported. CEO Geoff Martha noted, "Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor."
A standout within the results was Cardiac Ablation Solutions, which posted 78% global revenue growth — including 124% growth in the United States — gaining an additional eight points of U.S. market share. Alongside the earnings beat, Medtronic’s board approved a quarterly dividend increase to $0.72 per share, marking the company’s 49th consecutive annual dividend hike. Following the results, BTIG upgraded the stock from Neutral to Buy with a $90 price target. "MDT has demonstrated consistent MSD organic growth the past several quarters, and the trajectory is improving," analyst Sean Lavin said.
The broader market provided a mixed backdrop today, with the Dow Jones gaining +1.37% while the S&P 500 was essentially flat and the NASDAQ slipped slightly. The Healthcare Services & Equipment sector advanced modestly, but Medtronic’s move far outpaced peers. The company’s FY2027 organic revenue growth guidance of 6.75%–7.25% and a pipeline of strategic investments — including the pending ~$650 million acquisition of SPR Therapeutics and new stakes in cardiac catheter technology companies — reinforced investor confidence in the company’s growth trajectory.
Taken together, the combination of a decisive earnings beat, record annual revenue growth, a continued dividend increase, and credible forward guidance gave investors the conviction to drive MDT sharply higher, pushing the stock well off its 52-week low of $73.31 and toward levels last seen earlier in the year, even as the stock remains well below its 52-week high of $106.33.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates MDT every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could MDT be next—or is there a better opportunity in the same space?Don't wait to find out.